Kopran share price
NSE: KOPRANPharma & HealthcareDrug Manufacturers - General
Kopran at a glance
Kopran (NSE: KOPRAN) closed at ₹274.00 on 22 Oct 2026, up 3.16% on the day. With a market capitalisation of ₹1,323 Cr, it ranks 1332nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - General.
At its last close the stock traded at 51.4× trailing earnings, against a return on equity of 4.9% in FY26. Over the past year the share price has risen 64.0%. Its 52-week range is ₹107.00 (30 Mar 2026) to ₹295.83 (30 Sep 2026); the last close is 7.4% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹234 Cr (+33.4% year on year) and net profit ₹19 Cr (+94.9%), on a consolidated basis. Promoters held 44.42% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹1,323 CrRank 1332 on NSE
- P/E (trailing)
- 51.4×
- Price to book
- 0.98×FY26
- EPS (TTM)
- ₹5.79to Q4 FY26
- ROE
- 4.9%FY26
- ROCE
- 8.0%FY26
- Debt to equity
- 0.29FY26
- Net profit margin
- 3.8%FY26
- Book value / share
- ₹109.82FY26
- 52-week high
- ₹295.8330 Sep 2026
- 52-week low
- ₹107.0030 Mar 2026
- 1-year return
- +64.0%
- RSI (14-day)
- 54.8
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +3.16% | −3.4% | −2.8% | +35.6% | +64.0% |
Kopran quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹139 Cr | ₹152 Cr | ₹166 Cr | ₹175 Cr | ₹138 Cr | ₹118 Cr | ₹194 Cr | ₹234 Cr |
| Revenue YoY | +19.2% | −0.7% | +4.6% | −5.7% | −1.3% | −22.2% | +16.9% | +33.4% |
| Net profit | ₹11 Cr | ₹7 Cr | ₹10 Cr | ₹10 Cr | ₹7 Cr | −₹10 Cr | ₹9 Cr | ₹19 Cr |
| Net profit YoY | +300.7% | −46.4% | −34.1% | −48.0% | −32.9% | −234.4% | −10.2% | +94.9% |
| Net margin | 8.0% | 4.9% | 6.3% | 5.5% | 5.4% | −8.4% | 4.8% | 8.1% |
| EPS | ₹2.30 | ₹1.53 | ₹2.16 | ₹2.01 | ₹2.01 | −₹2.06 | ₹1.93 | ₹3.91 |
Kopran financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹492 Cr | ₹478 Cr | ₹551 Cr | ₹615 Cr | ₹630 Cr | — |
| Operating profit | ₹83 Cr | ₹82 Cr | ₹36 Cr | ₹68 Cr | ₹52 Cr | — |
| Net profit | ₹62 Cr | ₹61 Cr | ₹27 Cr | ₹51 Cr | ₹39 Cr | — |
| EPS (₹) | ₹14.00 | ₹14.00 | ₹6.00 | ₹11.00 | ₹8.00 | — |
| Cash from operations | ₹60 Cr | −₹33 Cr | ₹34 Cr | ₹43 Cr | ₹42 Cr | — |
| Total debt | ₹21 Cr | ₹19 Cr | ₹18 Cr | ₹17 Cr | ₹16 Cr | ₹14 Cr |
| Shareholders' equity | ₹245 Cr | ₹426 Cr | ₹439 Cr | ₹491 Cr | ₹518 Cr | ₹530 Cr |
Kopran shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 44.42% | 44.42% | 44.42% | 44.42% | 44.42% | 44.42% |
| Foreign institutions | 1.12% | 0.76% | 0.60% | 0.36% | 0.57% | 0.51% |
| Domestic institutions | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Non-institutions | 54.45% | 54.82% | 54.98% | 55.22% | 55.00% | 55.06% |
Kopran vs peers
The listed Pharma & Healthcare companies nearest to Kopran by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| AMRUTANJANAmrutanjan Health Care | ₹496.20 | +0.45% | −29.1% | ₹1,435 Cr | 24.8 | — |
| JAGSNPHARMJagsonpal Ser | ₹216.03 | −1.13% | +2.0% | ₹1,422 Cr | 34.2 | — |
| TTKHLTCARETTK Healthcare | ₹994.70 | +3.29% | −11.6% | ₹1,406 Cr | 21.4 | — |
| FERMENTAFermenta Biotech | ₹466.35 | −0.78% | — | ₹1,373 Cr | — | — |
| KOPRANKopran | ₹274.00 | +3.16% | +64.0% | ₹1,323 Cr | 51.4 | — |
| AHCLAnlon Healthcare | ₹24.35 | −4.99% | +90.4% | ₹1,294 Cr | 39.9 | — |
| SHALBYShalby | ₹118.16 | −1.53% | −52.1% | ₹1,276 Cr | 36.5 | — |
Ask anything about Kopran
Pivot answers on the live chart with evidence you can check, and tests strategies against KOPRAN's own history. Try: “Why has KOPRAN moved over the last three months?” · “Backtest a 50-day moving-average crossover on KOPRAN over five years” · “Compare KOPRAN with AMRUTANJAN on margins and valuation”
Frequently asked questions about Kopran
What is the share price of Kopran today?
Kopran (NSE: KOPRAN) last closed at ₹274.00 on 22 Oct 2026. Its 52-week high is ₹295.83 and its 52-week low is ₹107.00.
What is the market cap of Kopran?
Kopran's market capitalisation is ₹1,323 Cr (₹1,323 Cr) at the 22 Oct 2026 close, ranking 1332nd among the NSE companies Pivot tracks.
What is the P/E ratio of Kopran?
Kopran trades at a trailing P/E of 51.4. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 34.2.
What is the ROE and ROCE of Kopran?
Return on equity was 4.9% in FY26 and return on capital employed was 8.0% in FY26 (consolidated figures).
Is Kopran a debt-free company?
No. Kopran's debt-to-equity ratio was 0.29 in FY26, with total debt of ₹14 Cr.
What were Kopran's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Kopran reported revenue of ₹234 Cr, +33.4% year on year, and net profit of ₹19 Cr, +94.9% year on year.
How has Kopran stock performed over the last year?
Kopran's share price has risen 64.0% over the past year, +35.6% over three months and −2.8% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Kopran?
As of 30 Jun 2026: promoters 44.42%, foreign institutions 0.51%, domestic institutions 0.00%, non-institutions 55.06%.
Who are Kopran's competitors?
The listed Pharma & Healthcare companies closest to Kopran by market cap are Amrutanjan Health Care, Jagsonpal Ser, TTK Healthcare, Fermenta Biotech, Anlon Healthcare and Shalby.
Is Kopran a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Kopran's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on KOPRAN against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with K · all NSE stocks · this page as text